Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp318 | Osteoporosis: treatment | ECTS2014

Preferences of patients and health care professionals for osteoporosis drug treatment: a discrete choice experiment

Hiligsmann Mickael , Dirksen Carmen , Dellaert Benedict , van der Weijden Trudy , Goemaere Stefan , Reginster Jean-Yves , Watson Verity , Boonen Annelies

Objectives: This study aims to evaluate and compare the preferences of patients and health care professionals for osteoporotic drug treatment.Materials and methods: A discrete choice experiment was conducted among patients and health care professionals (general physicians, rheumatologists, and geriatricians) in Belgium. Participants were asked to choose between two hypothetical unlabelled drug treatments (and an opt-out option) that vary in several attri...

ba0003oc6.4 | Osteoporosis treatment and the effects of physical activity | ECTS2014

Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years

Ferrari S , Adachi JD , Lippuner K , Zapalowski C , Miller PD , Reginster J-Y , Torring O , Kendler DL , Daizadeh N , Wang A , O'Malley CD , Wagman RB , Libanati C , Lewiecki EM

Objective: Evidence for further reduction of nonvertebral fracture (NVFX) beyond 3 years of antiresorptive therapy is limited. Since long-term denosumab (DMAb) treatment is associated with continuous increases in BMD and sustained fracture reduction, we analyzed the influence of femoral neck (FN) BMD after 3 years on NVFX rates.Methods: Long-term subjects received 7 continuous years of DMAb; cross-over subjects received 3 years of placebo (FREEDOM) and 4...

ba0005oc1.4 | Clinical trials and osteoporosis treatment | ECTS2016

Relationship between total hip (TH) BMD T-score and incidence of nonvertebral fracture (NVFX) with up to 10 years of Denosumab (Dmab) treatment

Ferrari S , Adami S , Brown J P , Cosman F , Czerwiński E , de Gregorio L H , Malouf J , Reginster J-Y , Daizadeh N S , Wang A , Wagman R B , Lewiecki E M

The relationship between BMD T-score and FX risk has not been established in patients receiving osteoporosis therapy. In the FREEDOM Extension study, continuous DMAb therapy for up to 10 years increased BMD levels with no therapeutic plateau at lumbar spine or TH [Bone et al, ASBMR 2015]. Such improvements would only be meaningful if associated with FX reductions. We investigated the relationship between TH BMD T-score and NVFX in women who received DMAb during FREEDOM and tho...

ba0003oc2.1 | Osteoporosis epidemiology | ECTS2014

Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures – the openthyro register cohort

Abrahamsen Bo , Jorgensen Henrik L , Laulund Anne S , Nybo Mads , Brix Thomas H , Hegedus Laszlo

Objective: To assess the relationship between thyrotoxicosis and osteoporotic fractures in men and women.Design: Register-based cohort study in patients with a TSH measurement in the region of Funen 1996–2010. All determinations were done in the same lab serving all hospitals and GP practices. Persons with raised TSH or a history of thyroid/pituitary disease were not included.Results: The study population consisted of 222 138 ...

ba0001pp436 | Osteoporosis: treatment | ECTS2013

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Recknor Christopher , Roux Christian , Ho Pei-Ran , Hall Jesse , Bone Henry , Bonnick Sydney , van den Bergh Joop , Ferreira Irene , Wagman Rachel , Brown Jacques P

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...

ba0001pp398 | Osteoporosis: treatment | ECTS2013

Health economic consequences of fractures in patients with osteoporosis: a national register based study of total and incremental health costs following fracture

Olsen Kim Rose , Hansen Carrinna , Abrahamsen Bo

Introduction: Osteoporotic fractures are known to be costly to society but estimates tend to be based on small scale prospective studies. In the following we report national data for healthcare costs due to fractures in patients with osteoporosis.Study population and methods: All Danish residents aged 35+, mean age 70.5 years, 13% men, 27.3% prior major osteoporotic fracture, who began bisphosphonates for osteoporosis between 1/1997 and 12/2002 (n</e...

ba0003oc6.6 | Osteoporosis treatment and the effects of physical activity | ECTS2014

External auditory canal and middle ear diseases in bisphosphonate-treated osteoporosis patients: A Danish national register based cohort study

Thorsteinsson Anne-Luise , Vestergaard Peter , Eiken Pia

Background and aim: Eight cases of bisphosphonate-associated osteonecrosis of the external auditory canal have been reported in case-reports. Our aim was to describe the incidence of external auditory canal and middle ear diseases in Danish patients exposed to bisphosphonates in the treatment of osteoporosis.Methods: The study was a retrospective, nationwide cohort study, within the Danish population of approximately 5.6 million individuals and based on ...

ba0001pp113 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Lower bone turnover in obesity: is there a link to energy metabolism?

Viljakainen Heli , Ivaska Kaisa K , Lipsanen-Nyman Marita , Saukkonen Tero , Andersson Sture , Laitinen Kalevi , Makitie Outi

Background: Observations in rodents suggest that osteocalcin (OC) participates in glucose metabolism. Data from human studies are inconclusive and it remains unclear whether OC is simply a marker of bone turnover (BTM) or if it also mediates interactions between the skeleton and glucose homeostasis. This study determined the responses of BTMs, including OC, to oral glucose tolerance test (OGTT) in obese and normal-weight subjects.Materials and methods: P...

ba0001pp243 | Cell biology: osteocytes | ECTS2013

Single osteocyte gene expression in an in vivo model for load-induced bone adaptation

Wilson Robin , Trussel Andreas , Webster Duncan , Kurth Felix , Dittrich Petra , Muller Ralph

It is hypothesized that osteocytes regulate bone adaptation by sensing mechanical strains in their microenvironments and signaling net bone formation or resorption. Owing to bone’s anisotropic architecture, individual osteocytes within a bone experience varying strains under mechanical loading. Thus, to accurately determine the relationships between mechanical strain, osteocyte behavior, and bone remodeling, it is crucial to use a single-cell approach. Using an in viv...